Research & Development: Page 27

  • missing target
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 impactful drug trial failures from the last year

    Major recent trial flops and what they mean for companies, patients and the industry.

    By • Oct. 19, 2022
  • Scientific illustration of a migrating breast cancer cell
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A new class of drugs with ‘huge’ potential in the fight against challenging breast cancers

    Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.

    By Kelly Bilodeau • Oct. 18, 2022
  • digital pill Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • black scientist
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The Novartis U.S. Foundation’s president on the ‘magical piece’ of its 10-year health equity plan

    Dr. Patrice Matchaba discusses Novartis’ end-to-end approach to tackling systemic health disparities.

    By • Oct. 17, 2022
  • Ryan Moslin, senior principal scientist, Bristol Myers Squibb
    Image attribution tooltip
    Permission granted by BMS / Ryan Moslin
    Image attribution tooltip
    Q&A

    He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma

    Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.

    By • Oct. 17, 2022
  • Medical professional in lab working on tablet.
    Image attribution tooltip
    Permission granted by Park & Battery
    Image attribution tooltip
    Sponsored by PPD

    Survey: The Top 5 Innovations and New Operational Strategies in Pharmaceutical R&D

    According to a recent survey conducted by PPD, part of Thermo Fisher Scientific, 98% of drug developers report that, in the wake of COVID-19, they have embraced a wealth of new strategies across the entire clinical trial lifecycle – from adaptive trial design to big data. Find out how to apply these trends to your innovative clinical programs.

    Oct. 17, 2022
  • woman checking her cell phone for provasic
    Image attribution tooltip
    Permission granted by GoodRx
    Image attribution tooltip
    Sponsored by GoodRx

    Does your copay program factor in differences across specialties? GoodRx analysis shows it should.

    New findings reveal an out-of-pocket cost gap between brand-name and generic prescriptions. To address this gap, GoodRx is partnering with pharmaceutical companies to improve cost transparency and communication between patients and providers.  

    Oct. 17, 2022
  • A wooden figurine of a business person sits at a higher spot on a table than a series of six other wooden figurines of business people.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Making Moves

    BIO’s interim CEO and Alvotech’s new chief quality officer could spell big changes for biotech

    What these life science organizations’ latest executive-level appointments mean for the industry.

    By Karissa Waddick • Oct. 14, 2022
  • Subvariant virus spreading as viral pathogens
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses

    President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.

    By Kelly Bilodeau • Oct. 13, 2022
  • Green capsule medicine pill fall out of a production line.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Robotic pills could open a world of possibilities for the biologics market

    As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions. 

    By Karissa Waddick • Oct. 13, 2022
  • Ameet Mallik horizontal
    Image attribution tooltip
    Permission granted by Ameet Mallik
    Image attribution tooltip
    Q&A

    Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology

    The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.

    By • Oct. 12, 2022
  • Young African American biochemist using microscope while working on scientific research in a laboratory. The view is through the glass.
    Image attribution tooltip
    skynesher via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets

    CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.

    By Karissa Waddick • Oct. 11, 2022
  • Amit Etkin horizontal
    Image attribution tooltip
    Permission granted by Amit Etkin
    Image attribution tooltip
    Profile

    Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

    After making the leap from academia to the world of biotech, CEO Dr. Amit Etkin is hoping to shift the treatment paradigm for neurological conditions.

    By Alexandra Pecci • Oct. 11, 2022
  • Closeup shot of an unrecognizable doctor using a digital tablet.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The digital therapeutics revolution is happening and Big Pharma is buying in — with caution

    Companies like Pfizer, Novartis, Sanofi and BMS are diving into the world of digital therapeutics while recognizing the limitations of the young field.

    By • Oct. 10, 2022
  • Silhouettes of two people colored in a swirling spectrum of colors. They are against a background of other spectrum colors and shapes.
    Image attribution tooltip
    Stan Eales via Getty Images
    Image attribution tooltip
    Q&A

    New partnership may give MDMA an edge in the psychedelics space

    While LSD and psilocybin steal the spotlight, drug developers are also exploring MDMA for a wide swath of neurological illnesses. 

    By Kelly Bilodeau • Oct. 10, 2022
  • Fiona Elwood B&W WoW header
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Image attribution tooltip
    Podcast

    Woman of the Week: Janssen’s Fiona Elwood

    The neurodegeneration lead at Janssen is driving precision-based medicine to better understand the pathology of neurological disease for the greatest patient impact.

    By • Oct. 5, 2022
  • cell therapy infusion
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    It’s electric — speeding up the cell therapy process for scalability

    To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

    By Alexandra Pecci • Oct. 4, 2022
  • hiring stock
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The 2 areas in life sciences most in need of talent

    The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.

    By • Oct. 4, 2022
  • Cancer cells
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    To stay on the leading edge of oncology, AbbVie knows it has to take risks

    In a field that has seen rapid progress but ongoing areas of unmet need, AbbVie is betting on emerging tech.

    By Kelly Bilodeau • Oct. 4, 2022
  • digital clinical trials
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    Clinical trials haven’t harnessed the digital revolution — TransCelerate’s latest initiative aims to change that

    The nonprofit’s VP of portfolio management discussed its “most transformative” digital initiative to date.

    By PharmaVoice staff • Oct. 3, 2022
  • Merck sign
    Image attribution tooltip
    Marko Georgiev / Stringer via Getty Images
    Image attribution tooltip
    Q&A

    Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut

    Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.

    By • Oct. 3, 2022
  • A scale is foregrounded against the sky.
    Image attribution tooltip
    zennie via Getty Images
    Image attribution tooltip

    How do Biogen-Eisai’s two Alzheimer’s drugs stack up?

    Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.

    By • Sept. 30, 2022
  • Samantha Dale Strasser headshot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Image attribution tooltip
    Podcast

    Woman of the Week: Pepper Bio’s Samantha Dale Strasser

    The co-founder of Pepper Bio entered the biotech world three years ago with the goal of transforming drug discovery through the emerging discipline of transomics.

    By • Sept. 28, 2022
  • magic mushroom
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success

    The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression. 

    By • Sept. 27, 2022
  • Autism stock
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    Why precision medicine could be the next frontier in treating autism

    Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.

    By Kelly Bilodeau • Sept. 27, 2022
  • Methadone at home
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Methadone at home? Emerging tech provides new tool in the fight against opioid addiction

    Sonara Health’s inexpensive, specially engineered label and web app allow for at-home, digitally supervised dosing of high-cost or high-risks drugs.

    By Alexandra Pecci • Sept. 15, 2022